SciELO - Scientific Electronic Library Online

 
vol.10 número4Comportamiento clínico y radiológico de 290 implantes con superficie tratada mediante un primer grabado de ácido fluorhídrico y un segundo de ácido fluorhídrico con ácido nítrico: valoración a los dos años de carga precozAdenocarcinoma Polimorfo de Bajo Grado de fosa nasal índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Medicina Oral, Patología Oral y Cirugía Bucal (Ed. impresa)

versión impresa ISSN 1698-4447

Resumen

ALONSO, Juan et al. OK432 (picibanil) efficacy in an adult with cystic cervical lymphangioma: A case report. Med. oral patol. oral cir. bucal (Ed.impr.) [online]. 2005, vol.10, n.4, pp.362-366. ISSN 1698-4447.

Cervical cystic lymphangioma (CCL) is a rare and benign tumour involving congenital and cystic abnormalities derived from lymphatic vessels. The most accepted treatment continues to be surgical excision. However, when this infiltrates vital neurovascular neck structures, complete excision is difficult and if only partial, the recurrence rate is very high. The most frequently used alternative treatment is to inject sclerosants into the lesion. The use of these techniques has reported good results in children; however, there are few references thereof with regard to adults. We are reporting on a cervical cystic lymphangioma in a male aged 22, treated with an intra-lesion injection of 20 cc with 0.01 mg/cc dilution of OK-432 (picibanil) in physiological serum. Sole complications were fever and local reaction where the solution was injected. One month after treatment the lymphangioma had totally remitted and sixteen months later continues in remittance.

Palabras clave : OK432 (picibanil); Cervical cystic linphangioma; adult; efficacy.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons